Efficacy and Safety of Aficamten in Obstructive Hypertrophic Cardiomyopathy Patients Eligible for Septal Reduction Therapy: A FOREST-HCM Analysis

Exercise Performance With Aficamten vs Metoprolol in Obstructive Hypertrophic Cardiomyopathy: The MAPLE-HCM Randomized Clinical Trial

Serum Magnesium and Outcomes in Patients With Heart Failure and Reduced Ejection Fraction: Insights From the GALACTIC-HF Trial

Omecamtiv Mecarbil and Red Cell Distribution Width in Patients With Heart Failure and Reduced Ejection Fraction: Results From the GALACTIC-HF Trial

An Open-label Extension Study of Aficamten for Chinese Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy: 48-week Results

Towards a Quantitative Understanding of Aficamten Clinical Pharmacology: Pharmacokinetic-Cardiodynamic Modeling to Support Safety and Efficacy

Effect of Aficamten Compared with Metoprolol in Women vs. Men: Analysis of MAPLE-HCM

The Influence of QRS Duration and Resynchronization Status on the Efficacy and Safety of Omecamtiv Mecarbil in Heart Failure with Reduced Ejection Fraction: The GALACTIC-HF Trial

Dose-Dependent Effects of Aficamten Compared With Metoprolol in Obstructive HCM: The MAPLE-HCM Study

Favorable Effect of Aficamten on Left Atrial Mechanics in Obstructive Hypertrophic Cardiomyopathy: Insights from the SEQUOIA-HCM Trial